Smartleaf Asset Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 259.5% during the fourth quarter, according to its most recent filing ...

New York, USA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight The mucopolysaccharidosis ...

Regenxbio (RGNX) announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the ...

Learn more about whether Kymera Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's ...

Regenxbio closes strategic partnership with Nippon Shinyaku for MPS diseases: Rockville, Maryland Wednesday, March 5, 2025, 14:00 Hrs [IST] Regenxbio Inc., a leading clinical-stag ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sector ...

In February 2024, when she was five, Liliana was diagnosed with Morquio syndrome — also known as mucopolysaccharidosis type ...

REGENXBIO Inc.  today announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the agreement, REGENXBIO and Nippon Shinyaku will develop and ...

For the first time, Hospital Kuala Lumpur (HKL) is proudly hosting the annual Rare Disease Day 2025 celebration to raise ...

Last month, Regenxbio and Nippon Shinyaku announced a strategic partnership to develop and commercialize RGX-121 for Mucopolysaccharidosis II, also known as Hunter syndrome, and RGX-111 for ...

an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab ...